989 East Hillsdale Blvd.
Tel: (650) 209-4055
About Apollomics, Inc.
Apollomics, Inc. is an innovative biopharmaceutical company committed to bridging innovation from East and West to discover and develop oncology combination therapies that harness the immune system and target specific molecular pathways to defeat cancer globally. Apollomics’ existing pipeline consists of development-stage assets including novel, humanized monoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. At Apollomics, we are a purpose driven company imagining a world without cancer. We let science drive our decision making to advance our programs. We believe in the power of partnerships to enhance our pipeline and broaden the patient populations we serve.
32 articles with Apollomics, Inc.
Apollomics, Inc. Receives China Investigational New Drug Approval for APL-102 to Initiate a Phase 1 Study
Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of new tumor-targeting agents and immuno-oncology agents and their combination therapies, today announced that APL-102 has received China Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the initiation of a Phase 1 pharmacokinetic
- Financing led by Ping An Capital - - Phase 2 SPARTA Trial for APL-101 Now Enrolling - - Phase 3 Clinical Trial to begin in China for APL-106 ( Uproleselan ) -
Apollomics, Inc. Receives China Investigational New Drug Approval for APL-106 to Initiate a Phase 3 Bridging Study in Acute Myeloid Leukemia
Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, announced APL-106 has received Investigational New Drug approval from the China National Medical Products Administration Center for Drug Evaluation.
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
Focus on non-small cell lung cancer with a mutation that leads to MET exon 14 skipping, and tumors with amplifications and MET fusions, including glioblastoma multiforme
GlycoMimetics and Apollomics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Uproleselan and GMI-1687 in Greater China
GlycoMimetics to receive an upfront cash payment with eligibility to receive development, regulatory, and sales-based milestones, and tiered royalties
5/3/2019Biopharma companies make changes to their C-suite leadership teams, with hires at uBiome, Enzyre, Sobi, Amylyx, Mission Therapeutics, and more.
Apollomics, Inc. announced that Fabio M. Benedetti, M.D. has joined the senior leadership team as Chief Medical Officer (CMO).
Apollomics, Inc. Presents Positive Preclinical Data on APL-102, an oral Multi-Kinase Inhibitor with CSF-1R Activity
Activity Demonstrated as a Single Agent and in Combination with an anti-PD-1 antibody
Wilson W. Cheung, CPA appointed Chief Financial Officer
Financing will accelerate development of the Company’s cancer immunotherapy and targeted therapy programs
CBT Pharmaceuticals and Strata Oncology Announce Collaboration to Accelerate Development of CBT-101, a c-Met inhibitor, for Patients with Non-Small Cell Lung Cancer and other Solid Tumors
Strata will exclusively refer Met-amplified, Met-mutation and Met-fusion advanced cancer patients identified through the Strata Trial for enrollment consideration into CBT's clinical development program for CBT-101.
CBT Pharmaceuticals and Zhejiang Bossan Pharmaceutical Enter into a Collaboration and License Agreement to Develop Combination Cancer Treatments
CBT’s c-Met inhibitor and anti-PD1 antibody to be evaluated in combination with Bossan’s EGFR inhibitor
CBT Pharmaceuticals Awarded NIH Small Business Innovation Research Grant Towards Development of Combination Checkpoint Inhibition
CBT Pharmaceuticals today announced it has been awarded a Small Business Innovation Research (SBIR) Grant from the U.S. Department of Health and Human Services National Cancer Institute (NCI) of the National Institutes of Health (NIH).
CBT Pharmaceuticalstoday announced the initiation of the APOLLO Oncology Clinical Trials Program.
CBT Pharmaceuticals Strengthens Management Team with the Appointment of Yuling Li, PhD as Senior Vice President, Process Development and Manufacturing
CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies, today announced a new global leadership structure and the appointment of Yuling Li, PhD as Senior Vice President, Process Development and Manufacturing.
CBT Pharmaceuticals Receives First Australian Ethics Approval to Initiate APOLLO-1 Phase 1/2 Clinical Trial for Hepatocellular and Renal Cell Carcinoma
CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies, today announced the receipt of ethics approval from the Bellberry Human Research Ethics Committee (HREC) in Australia for its planned APOLLO-1 clinical trial.
CBT Pharmaceuticals Initiates Phase 1b Clinical Trial for Anti-PD-1 Antibody CBT-501-01 (genolimzumab injection) in Patients with Advanced Solid Tumors
CBT Pharmaceuticals today announced the continuation of the CBT-501 Phase 1 clinical trial with the initiation of the Phase 1b segment of the study in patients with select advanced or relapsed/recurrent solid tumors.
CBT Pharmaceuticals and CrystalGenomics Announce Partnership for Co-development of Global Immuno-Oncology Therapy
CBT Pharmaceuticals (CBT) and CrystalGenomics, Inc., (KOSDAQ:083790) today announced a co-development agreement for an investigational combination therapy of CBT-501 and CG200745 across a variety of solid tumors with high unmet medical needs.
Now in its fourth day, the American Association of Cancer Research (AACR) Annual Meeting 2018 held in Chicago, has had plenty of news, much of it preclinical or early-clinical data.